Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

EverSlim vs MyStart Health

EverSlim
Graded #68

Higher grade

vs+6.400000000000006
MyStart Health
Graded #168

Lower grade

The verdict

EverSlim takes it — 73.5/100 to 67.1/100.

EverSlim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. EverSlim is a US telehealth programme selling doctor-prescribed compounded GLP-1 medication delivered to the door, with compounded semaglutide from $117 a month and compounded tirzepatide from $140 a month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEverSlim +32
80
48
Dose & formulationMyStart Health +19
64
83
Clinical oversightMyStart Health +8
76
84
Labs & monitoringMyStart Health +3
63
66
FulfillmentEverSlim +19
97
78
Contract termsEverSlim +24
55
31
EverSlim · left barMyStart Health · right bar

The numbers

MetricEverSlimMyStart Health
WeighScore73.5/10067.1/100
GradeCC
Scorecard rank#68#168
Semaglutide$117/mo (compounded)$299/mo (all doses, compounded)
Tirzepatide$140/mo (compounded)$299/mo (all doses, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
EverSlim

Graded #68 · C

Strengths

  • Transparent flat pricing from 127 dollars a month for compounded semaglutide; medication, provider visit, and shipping included with no insurance.
  • Names its pharmacy partners (EPIQ Scripts, Foothills, Emerald) and DrTelx medical group; LegitScript-approved and NABP-accredited.
  • Available in all 50 states and DC, with asynchronous care in 44 states and live-visit access in the rest.
  • Offers both semaglutide and tirzepatide, plus care-team messaging between visits.

Where it loses points

  • No price tiers are published anywhere: /pricing is a 404, the footer pricing link is a same-page anchor, and the checkout is behind a login, so what a titrated dose costs is unknowable before signing up
  • Cancellation requires at least 72 hours' notice before the next billing date, or the subscription renews for another cycle
  • Asynchronous care covers 44 states; DC, Kansas, Louisiana, Mississippi, New Mexico, Rhode Island and West Virginia require a live video consult
  • Marketing says 'No membership' while the cancellation policy repeatedly calls it a membership and a subscription
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
MyStart Health

Graded #168 · C

Strengths

  • Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
  • Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
  • 24/7 care team access with unlimited clinician messaging included
  • LegitScript certified
  • Clear Section 503A compounding disclosure on every landing page

Where it loses points

  • Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
  • Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
  • Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
  • Very new company (incorporated May 2024) with a limited track record
  • Pharmacy partners not named, so 503A compliance can't be independently verified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard